ORIGINAL ARTICLE

Mangromicins A and B: structure and antitrypanosomal activity of two new cyclopentadecane compounds from *Lechevalieria aerocolonigenes* K10-0216

Takuji Nakashima¹, Masato Iwatsuki^{2,3}, Junya Ochiai³, Yoshiyuki Kamiya³, Kenichiro Nagai⁴, Atsuko Matsumoto^{2,3}, Aki Ishiyama², Kazuhiko Ootoguro², Kazuro Shiomi^{2,3}, Yōko Takahashi^{2,3} and Satoshi Ōmura²

Two new cyclopentadecane antibiotics, named mangromicins A and B, were separated out from the culture broth of *Lechevalieria aerocolonigenes* K10-0216 by Diaion HP-20, silica gel and ODS column chromatography, and were finally purified by HPLC. The chemical structures of the two novel compounds were elucidated by instrumental analyses, including various NMR, MS and X-ray crystallography. Mangromicins A and B consist of cyclopentadecane skeletons with a tetrahydrofuran unit and a 5,6-dihydro-4-hydroxy-2-pyrone moiety. Mangromicins A and B showed *in vitro* antitrypanosomal activity with IC₅₀ values of 2.4 and 43.4 µg ml⁻¹, respectively. The IC₅₀ values of both compounds were lower than those of cytotoxicity against MRC-5 human fetal lung fibroblast cells.

The Journal of Antibiotics (2014) 67, 253–260; doi:10.1038/ja.2013.129; published online 11 December 2013

Keywords: antitrypanosomal activity; *Lechevalieria aerocolonigenes*; mangromicins; mangrove sediment; physicochemical screening

INTRODUCTION

The myriad and complex biosynthetic routes involved in natural product chemistry result in almost limitless chemical diversity with numerous chemicals exhibiting a wide range of useful bioactivity. Natural products arising from microorganisms have played a pivotal role in drug discovery for more than a century.¹ Actinomycetes have long been recognized as prolific producers of useful bioactive metabolites that have demonstrated a broad spectrum of bioactivity,^{2,3} and they possess >20 secondary metabolic biosynthesis gene clusters.^{4–7} However, the expression of secondary metabolite genes is remarkably influenced by environmental factors; such as, temperature, aeration, cultivation time and nutrients.^{8,9} Although it is widely believed that many more useful compounds will be discovered from the secondary metabolites of actinomycetes, as long as culture conditions are optimized, it is getting increasingly difficult to discover and develop new natural product-based therapeutic drugs for clinical studies.¹⁰

We have a long history of undertaking biological screening programs to try and find new useful compounds from microorganisms. However, in these biological screening programs, in cases where

the production of metabolites only creates minute amounts of a compound or where specific biological assays are unsuitable or non-existent, it is possible to miss or overlook potential and valuable compounds. Fortunately, chemical screening systems complement biological screening systems and allow for detection of even minute amounts of any compound. Secondary metabolites in a fermentation broth can be detected by analytical method (e.g. HPLC-MS) or color reaction (e.g. Dragendorff's reagent). Even if we cannot identify useful biological activities of new compounds using currently available biological assays, it is possible that any pure compound can be tested at a later date and may be developed as a potentially useful drug or drug lead in the future. As an example, staurosporine was discovered from secondary metabolites of *Streptomyces* sp. AM-2282¹¹ (present strain name is *Lentzea albida*¹² via *Saccharothrix aerocolonigenes* subsp. *staurosporeus*¹³) in 1977 while screening to detect alkaloids using Dragendorff's reagent. It was originally found to exhibit antifungal properties.¹¹ In 1986, nine years after discovery, staurosporine was found to be a nanomolar inhibitor of protein kinases, through the prevention of ATP binding to the kinase.^{14,15} The interesting biological activity stimulated exploratory

¹Research Organization for Infection Control Sciences, Kitasato University, Tokyo, Japan; ²Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan; ³Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan and ⁴Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan
Correspondence: Dr T Nakashima, Research Organization for Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.
E-mail: takuji@lisci.kitasato-u.ac.jp
or Professor Y Takahashi, Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.
E-mail: ytakaha@lisci.kitasato-u.ac.jp

Received 17 August 2013; revised 28 September 2013; accepted 25 October 2013; published online 11 December 2013

research on staurosporine derivatives and selective protein kinase inhibitors by many laboratories and pharmaceutical companies, eventually resulting in the development of imatinib,¹⁶ an anticancer agent that entered human clinical trials for chronic myelogenous leukemia in 1998, being approved for use in the United States in 2001.¹⁷

We have paid attention to the isolation and purification of novel compounds from cultured broths of microorganisms using an approach based on the physicochemical properties of compounds, using HPLC-UV detection (LC/UV), -MS (LC/MS) system and color reaction. Peaks originating from unknown compounds can be identified using existing databases, such as the Dictionary of Natural Products (<http://dnp.chemnetbase.com/>), as well as in-house databases. We refer to this method as physicochemical screening. The ongoing physicochemical screening program has recently discovered two new cyclopentadecane compounds with a 5,6-dihydro-4-hydroxy-2-pyrone ring and a tetrahydrofuran unit, which have been named mangromicins A (1) and B (2).^{18,19} The compounds were discovered in a cultured broth of actinomycete strain K10-0216, which was isolated from a mangrove sediment sample collected on Iriomote Island, Japan. The producing organism was subsequently identified to be the rare actinomycete, *Lechevalieria aerocolonigenes*. Mangromicins A (1) and B (2) exhibited antitrypanosomal activity.

RESULTS AND DISCUSSION

Taxonomy of the producing strain, *L. aerocolonigenes* K10-0216

Strain K10-0216 was isolated from a mangrove sediment sample collected on Iriomote Island, Japan. The strain grew well on yeast extract–malt extract agar, inorganic salts–starch agar, oatmeal agar and others, but weakly on glucose–asparagine agar, tyrosine agar and glucose–nitrate agar. The colony color was yellowish brown. Extremely sparse white aerial mycelia were only produced on inorganic salts–starch agar and formed clumps of interwoven hyphae (Figure 1). No soluble pigment was produced. Whole-cell hydrolysates contained *meso*-diaminopimelic acid. The predominant menaquinone of the strain was MK-9 (H₄). The 16S rRNA gene sequence (1394 nucleotides) was determined and analyzed using the EzTaxon-e database (<http://eztaxon-e.ezbiocloud.net/>) and was closely related to *L. aerocolonigenes* ISP 5034^T (AB020030, similarity: 99.8%). These results showed that this strain belonged to genus *Lechevalieria*.²⁰ The phylogenetic tree also supported the result (Supplementary Figure S1). On the basis of the morphological and cultural properties and 16S rRNA gene sequence analyses, strain K10-0216 is identified with *L. aerocolonigenes*.

Isolation of mangromicins A (1) and B (2)

Isolation of mangromicins was guided by physicochemical screening using LC/UV and LC/MS equipments. The procedure for isolation of compounds 1 and 2 is summarized in Scheme 1. The whole culture broth (15 l) was centrifuged to separate the mycelium and supernatant. The supernatant was passed through a column of Diaion HP-20 (100 i.d. × 250 mm; Mitsubishi Chemical, Tokyo, Japan) previously equilibrated with water. After washing with water and 40% MeOH, the fraction containing the mangromicins was eluted with 100% MeOH. The whole eluate was concentrated *in vacuo* to dryness, yielding 5.6 g of material. This material was subjected to column chromatography on silica gel FL100D (60 i.d. × 200 mm; Fuji Silysia Chemical, Aichi, Japan), eluted with a stepwise gradient of CHCl₃–MeOH (100:0, 100:1, 50:1, 10:1, 1:1 and 0:100 (v/v)), to give six fractions. The eluate fractions (100:1 and 50:1 fractions) were combined and concentrated to yield 780 mg. The material was applied

Figure 1 Scanning electron micrograph of aerial mycelia of *Lechevalieria aerocolonigenes* K10-0216 grown on (a) and (b) inorganic salts–starch agar at 27 °C for 4 weeks.

Scheme 1 Purification of mangromicins A (1) and B (2).

on an ODS column (40 i.d. $\times$ 150 mm; Senshu Scientific, Tokyo, Japan) previously equilibrated with water. After washing with water and 40% MeOH, the fractions containing mangromicins were eluted with 50 and 60% MeOH and concentrated *in vacuo*. The eluate fractions (105 mg) were dissolved in a small amount of MeOH and purified by HPLC on an Inertsil ODS-4 column (10 i.d. $\times$ 250 mm; GL Sciences) with 40% MeOH at 4.7 ml min⁻¹ and subsequently

detected at UV 254 nm. The yields of mangromicins A (1) and B (2) were 9.0 and 10.3 mg, respectively.

Physico-chemical properties of mangromicins A (1) and B (2)

The physico-chemical properties of compounds 1 and 2 are summarized in Table 1. They are readily soluble in MeOH and EtOH but not benzene and CHCl₃. Compounds 1 and 2 showed absorption maxima at 251 and 236 nm in UV spectra, respectively. The IR absorption at 3440 and 1637 cm⁻¹ in 1, and 3450 and 1672 cm⁻¹ in 2 suggested the presence of hydroxyl and carbonyl groups, respectively. The similarity in physico-chemical properties strongly suggested that these two compounds are structurally related.

Structure elucidation of mangromicin A (1)

Mangromicin A (1) was obtained as a pale yellow powder or a colorless needle crystal determined to have the molecular formula of C₂₂H₃₄O₇ by HR-ESI-MS [M + H]⁺ *m/z* 411.2377 (calcd. for C₂₂H₃₄O₇, 411.2383) and NMR spectral data. The 1D and 2D NMR spectra of 1 were mainly obtained in CD₃OD. As some broadening signals were observed in CD₃OD, the ¹H and ¹³C spectra of 1 in DMSO-*d*₆ were also measured at 80 °C to yield sharp signals.

The ¹H and ¹³C NMR spectral data of 1 are listed in Table 2. The ¹H NMR data indicated the presence of four oxygenated *sp*³ methines, three *sp*³ methine protons containing two methine ones coupled to methyl groups, six methylenes, one primary methyl, two secondary methyls and one tertiary methyl. The ¹³C NMR spectrum showed the resonances of 22 carbons, which were classified into two olefinic carbons, two carbonyl carbons at δ_c 169.3 and 208.8, one oxygenated

Table 1 Physico-chemical properties of mangromicins A (1) and B (2)

	Mangromicin A (1)	Mangromicin B (2)
Appearance	Pale yellow or colorless needle	Pale yellow
Molecular formula	C ₂₂ H ₃₄ O ₇	C ₂₂ H ₃₂ O ₆
MW	410	392
ESI-MS(<i>m/z</i>)		
Calcd.	411.2383 (for C ₂₂ H ₃₅ O ₇)	393.2277 (for C ₂₂ H ₃₃ O ₆)
Found	411.2377 [M + H] ⁺	393.2271 [M + H] ⁺
[α] _D ^{25.3} (c 0.1, MeOH)	−13.56	−24.08
UV $\lambda_{\max}$ (MeOH) nm	251 (2747)	236 (8036)
IR $\nu_{\max}^{\text{KBr}}$ cm ⁻¹	3440, 1637	3450, 1672
Solubility		
Soluble	MeOH, EtOH	MeOH, EtOH
Insoluble	Benzene, CHCl ₃	Benzene, CHCl ₃

Table 2 NMR spectroscopic data (CD₃OD, 400 MHz) for mangromicin A (1)

Position	δ_c , Mult	δ_H (int., mult., J in Hz)	HMBC
1	169.3, C		
2	103.5, C		
3	167.9, C		
4	44.4, CH	2.12 (1H, t, 7.0)	C-2, C-3, C-5, C-6, C-1', C-2'
5	73.8, CH	4.73 (1H, dd, 11.5, 1.8)	C-1, C-3, C-4, C-6, C-7, C-1'
6a	44.4, CH ₂	2.50 (1H, m)	C-5, C-7
6b		4.54 (1H, dd, 11.5, 18.9)	
7	208.8, C		
8	52.7, CH	2.75 (1H, qd, 7.1, 1.3)	C-7, C-9, C-10, C-8-Me
9	73.0, CH	4.29 (1H, dd, 8.4, 1.3)	C-8, C-10, C-8-Me
10	72.3, CH	3.34 (1H, d, 8.4)	C-8, C-9, C-11, C-12
11	80.3, CH	3.19 (1H, d, 8.0)	C-14
12	37.3, CH	2.55 (1H, m)	C-10, C-11, C-13, C-12-Me
13a	48.9, CH ₂	1.62 (1H, m)	C-11, C-12, C-14, C-15, C-12-Me, C-14-Me
13b		1.85 (1H, dd, 11.9, 11.9)	
14	85.0, C		
15a	37.4, CH ₂	1.27 (1H, ddd, 14.3, 3.6, 3.5)	C-2, C-13, C-14, C-16, C-14-Me
15b		2.43 (1H, ddd, 14.3, 13.6, 3.8)	
16a	19.3, CH ₂	2.05 (1H, ddd, 15.4, 13.6, 3.8)	C-1, C-2, C-3, C-14, C-15
16b		2.86 (1H, ddd, 15.4, 13.6, 3.5)	
1'	34.6, CH ₂	1.59 (2H, m)	C-3, C-4, C-5, C-2', C-3'
2'a	21.3, CH ₂	1.40 (1H, m)	C-4, C-1', C-3'
2'b		1.52 (1H, m)	
3' (Me)	14.4, CH ₃	0.95 (3H, t, 7.1)	C-1', C-2'
8-Me	8.5, CH ₃	1.03 (3H, d, 7.1)	C-7, C-8, C-9
12-Me	13.7, CH ₃	1.06 (3H, d, 7.1)	C-11, C-12, C-13
14-Me	24.7, CH ₃	1.35 (3H, s)	C-13, C-14, C-15

sp^3 quaternary carbon, four oxygenated sp^3 methine carbons, three sp^3 methine carbons, six sp^3 methylene carbons and four methyl carbons by HSQC spectra. The 1H - 1H COSY indicated the presence of five partial structures: (a) C-5/C-6; (b) C-9/C-10; (c) C-11/C-13 and C-12/C-12-Me; (d) C-8/C-8-Me; and (e) C-4/C-3' as shown in Figure 2. Analysis of HMBC data confirmed the presence of a 5,6-dihydro-4-hydroxy-2-pyrone moiety based on correlations from H-4 to C-2, C-3, C-5 and C-6; from H-5 to C-1, C-3, C-4 and C-1'; from H₂-15 to C-2 and C-16; and from H₂-16 to C-1, C-2, C-3 and C-15. The HMBC correlations from H-4 to C-1' and C-2'; from H-5 to C-1'; from H₂-1' to C-3, C-4, C-5, C-2' and C-3'; from H₂-2' to C-4, C-1' and C-3'; and from H₃-3' to C-1' and C-2' confirmed an *n*-propyl group linked to the C-4 position. A tetrahydrofuran unit was identified, based on HMBC correlations from H-11 to C-14, from H-12 to C-11 and C-13 and from H₂-13 to C-11, C-12 and C-14. Moreover, the correlations from H-12 to C-12-Me; from H₂-13 to C-12-Me and C-14-Me; from H₂-16 to C-14; from H₂-15 to C-13, C-14 and C-14-Me; from H₃-12-Me to C-11, C-12 and C-13; and from H₃-14-Me to C-13, C-14 and C-15 confirmed a secondary methyl and a tertiary methyl linked to C-12 and C-14 positions, respectively. These HMBC correlations also showed that 5,6-dihydro-4-hydroxy-2-pyrone moiety and tetrahydrofuran unit were connected by ethylene bond. Finally, the cyclopentadecane ring was confirmed by the HMBC correlations from H-5 to C-6 and C-7; from H₂-6 to C-5 and C-7; from H-8 to C-7, C-9, C-10 and C-8-Me; from H-9 to C-8, C-10 and C-8-Me; from H-10 to C-8, C-9, C-11 and C-12; from H₃-8-Me to C-7, C-8 and C-9; and from H-12 to C-10. Therefore, the planer structure of **1** was elucidated as shown in Figure 2, and it was designated as mangromicin A.

The relative configuration of **1** was estimated by 1H - 1H coupling constant analysis, differential NOE and ROESY experiments

Figure 2 1H - 1H COSY (bold) and selected HMBC (arrow) correlations of mangromicins A (**1**) and B (**2**).

(Figure 3). The ROESY correlations were observed between H-13b/H₃-12-Me and H-13b/H₃-14-Me. These results indicate that H₃-14-Me and H₃-12-Me are located on the identical face of tetrahydrofuran unit. Moreover, the ROESY correlations were observed between H-6b/H-9, H₃-8-Me/H-10 and H-10/H₃-12-Me, and NOE correlation at H-11/H-12. In addition, the coupling constants were observed between H-8 and H-9 (1.3 Hz), H-9 and H-10 (8.4 Hz) and H-10 and H-11 (0 Hz). Therefore, the relative configuration from C-8 to C-14 in **1** was determined as shown in Figure 3. Finally, the ROESY correlations were observed between H-4 and H-6a, and no coupling between H-4 and H-5. These results reveal that *n*-propyl at C-4 and methylene at C-6 bound to 5,6-dihydro-4-hydroxy-2-pyrone moiety is located on the opposite surface. Therefore, the relative configuration of **1** was proposed as shown in Figure 3.

The proposed relative configuration of **1** was confirmed by X-ray analysis of a single crystal (Figure 4). Final refinement of the data resulted in a Flack parameter -0.1 (3), which did not allow determination of its absolute configuration (CCDC 947034 contains the supplementary crystallographic data for compound **1**. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.) These results suggested that **1** has the relative configuration of $4R^*$, $5R^*$, $8R^*$, $9S^*$, $10R^*$, $11R^*$, $12S^*$ and $14S^*$ (Figure 5).

Figure 3 Key NOE or ROESY correlations (arrow line) and coupling constants (arrow dot) of mangromicins A (**1**) and B (**2**).

Figure 4 ORTEP (Oak Ridge Thermal-Ellipsoid Plot Program) plot of mangromicin A (**1**) with the displacement ellipsoids drawn at the 50% probability level.

Structure elucidation of mangromicin B (**2**)

Mangromicin B (**2**) was obtained as a pale yellow powder that was determined to have the molecular formula of $C_{22}H_{32}O_6$ by HR-ESI-MS $[M + H]^+$ m/z 393.2271 (calcd. for $C_{22}H_{33}O_6$, 393.2277). This result indicated that **2** had lost one oxygen atom and two hydrogen atoms from **1**, and the 1H and ^{13}C NMR spectra of **2** showed that they are highly analogous to those of **1** with a cyclopentadecane ring. The 1H and ^{13}C NMR spectra of **2** in CD_3OD could be obtained with dissolved and sharp signals.

The 1H and ^{13}C NMR spectral data of **2** are listed in Table 3. The 1H NMR data indicated the presence of three oxygenated sp^3 methines, one olefinic proton, two sp^3 methine protons containing one methine coupled to one methyl group, six methylenes, one primary methyl, one secondary methyl and two tertiary methyls. The ^{13}C NMR spectrum showed the resonances of 22 carbons, which were classified into four olefinic carbons, two carbonyl carbons at δ_c 168.4 and 205.2, one oxygenated sp^3 quaternary carbon, three oxygenated sp^3 methine carbons, two sp^3 methine carbons, six sp^3 methylene carbons and four methyl carbons by HSQC spectrum. The 1H - 1H COSY of **2** indicated the presence of four partial structures: (a) C-5/C-6; (b) C-8/C-13, C-8/C-8-Me, C-12/C-12-Me; (c) C-15/C-16; and (d) C-4/C-3' as shown in Figure 2.

Analysis of HMBC spectra confirmed the presence of a 5,6-dihydro-4-hydroxy-2-pyrone moiety as shown in Figure 2. In addition, the presence of hydroxy group at C-3 position was also determined by hydrogen-deuterium (H/D) exchange experiment in **2**.²¹ The δ_c value of C-3 was shifted from 167.386 to 168.497 and the value of $\Delta\delta$ was -1.1 p.p.m. ($\Delta\delta = \delta_c$ (p.p.m.) in $CD_3OD - \delta_c$ (p.p.m.) in CD_3OH) (Supplementary Table S1). This result suggested that a hydroxy group is connected to the C-3 position. In addition, tetrahydrofuran unit was deduced from the comparison of chemical shifts with **1** (C-11 at δ_c 80.3 and H-11 at δ_H 3.19, C-14 at δ_c 85.0 in **1**; C-11 at δ_c 84.4 and H-11 at δ_H 3.68, C-14 at δ_c 82.3 in **2**).

In comparison of chemical shifts of **2** with **1**, one olefin proton at δ_H 6.74 (H-9) instead of one methine proton δ_H 2.75 (H-8) and one oxygenated methine proton at δ_H 4.29 (H-9) of **1** and one tertiary methyl proton (δ_H 1.76) instead of one secondary methyl proton (δ_H 1.03) in **1** were confirmed in **2**. The HMBC correlations from

Figure 5 Relative configurations of mangromicins A (**1**) and B (**2**).

H₂-6 to C-7, C-8 and C-9; from H₃-8-Me to C-7, C-8 and C-9; and from H-10 to C-8 reveal that **2** have a trisubstituted olefin between C-8 and C-9. The trisubstituted olefin between C-8 and C-9 was found to have *E* configuration by the ROESY correlations between H₃-8-Me and H-10, and H-6b and H-9 (Figure 3). Therefore, the planer structure of **2** was elucidated as shown in Figure 2, and it was designated as mangromicin B.

The relative configuration of **2** was estimated by 1H - 1H coupling constant analysis, differential NOE and ROESY experiments (Figure 3). The ROESY correlations in **2** were almost similar to those in **1**. The ROESY correlations were observed between H-4/H₂-6, H-6b/H-9, H₃-8-Me/H-10, H₃-8-Me/H-11, H-10/H₃-12-Me, H₃-12-Me/H-13b and H-13b/H₃-14-Me, and H-14-Me/H-16b. In addition, the coupling constants were observed between H-9 and H-10 (9.0 Hz), and H-10 and H-11 (1.3 Hz). A coupling between H-4 and H-5 was not observed. These results suggested that **1** has the relative configuration of $4R^*$, $5R^*$, $10R^*$, $11R^*$, $12S^*$ and $14S^*$ (Figure 5).

Owing to the difficulties in determining the absolute stereochemistry of **2** by crystallization, efforts were focused toward chemical methods, notably the modified Mosher method.²²⁻²⁵ Subsequent interpretation of $\Delta\delta_{S-R}$ values for the α -methoxy- α -trifluoromethylphenylacetate (MTPA) derivative ((*R*)-MTPA ester, HR-ESI-MS $[M + H]^+$ m/z 609.2699; (*S*)-MTPA ester, HR-ESI-MS $[M + H]^+$ m/z 609.2667; calcd. for $C_{32}H_{39}F_3O_8$, m/z 609.2675)

Table 3 NMR spectroscopic data (CD₃OD, 400 MHz) for mangromicin B (2)

Position	δ_C , mult	δ_H (int., mult., J in Hz)	HMBC
1	168.4, C		
2	104.0, C		
3	167.4, C		
4	43.5, CH	2.29 (1H, dd, 7.6, 5.2)	C-2, C-3, C-5, C-6, C-1', C-2'
5	78.3, CH	4.62 (1H, dd, 11.9, 4.8)	C-1, C-3, C-4, C-7, C-1'
6a	43.3, CH ₂	2.18 (1H, dd, 11.7, 4.8)	C-4, C-5, C-7, C-8, (C-9)
6b		4.03 (1H, dd, 11.9, 11.7)	
7	205.2, C		
8	134.8, C		
9	150.7, CH	6.74 (1H, dq, 9.0, 1.0)	
10	69.9, CH	4.54 (1H, dd, 9.0, 1.3)	C-8
11	84.4, CH	3.68 (1H, dd, 8.6, 1.3)	C-9, C-10, C-12, C-13, C-12-Me
12	37.3, CH	2.53 (1H, m)	
13a	50.4, CH ₂	1.41 (1H, dd, 12.0, 8.4)	C-11, C-12, C-14, C-15, C-12-Me, C-14-Me
13b		1.97 (1H, dd, 12.0, 8.4)	
14	82.3, C		
15a	33.8, CH ₂	1.28 (1H, m) ^a	C-2, C-13, C-14, C-16, C-14-Me
15b		2.59 (1H, m)	
16a	20.1, CH ₂	2.05 (1H, ddd, 15.2, 4.4, 3.5)	C-1, C-2, C-3, C-14, C-15
16b		2.91 (1H, ddd, 15.2, 12.8, 3.6)	
1'a	36.4, CH ₂	1.56 (1H, m)	C-3, C-4, C-5, C-2', C-3'
1'b		1.60 (1H, m)	
2'a	20.7, CH ₂	1.36 (1H, m)	
2'b		1.43 (1H, m)	
3' (Me)	14.4, CH ₃	0.94 (3H, t, 7.4)	C-1', C-2'
8-Me	11.7, CH ₃	1.76 (3H, d, 1.0)	C-7, C-8, C-9
12-Me	16.5, CH ₃	1.23 (3H, d, 6.8)	C-11, C-12, C-13
14-Me	24.9, CH ₃	1.37 (3H, s)	C-13, C-14, C-15

^aOverlapped. Bracket means ⁴J coupling.**Table 4** Antitrypanosomal activity of mangromicins A (1) and B (2)

Compound	<i>IC</i> ₅₀ (μg ml ⁻¹)		<i>SI</i> ^a
	Antitrypanosomal activity ^b	Cytotoxicity ^c	
Mangromicin A	2.44	16.02	6.6
Mangromicin B	43.39	92.60	2.1
Suramin ^d	1.58	> 100	> 63
Eflornithine ^d	2.27	> 100	> 44

^aSelectivity index (SI) = *IC*₅₀ value of cytotoxicity/*IC*₅₀ value of antitrypanosomal activity.^b*In vitro* antitrypanosomal activity against *Trypanosoma brucei brucei* GUTat 3.1.^cCytotoxicity in MRC-5 cells.^dClinical antitrypanosomal drug.

yielded unreliable results. The $\Delta\delta_{S-R}$ values at H-9, H₃-12-Me and H₃-14-Me showed -0.19, 0.31 and -0.38, respectively. Therefore, the absolute configuration of **2** could not be determined by the modified Mosher's method (Supplementary Figure S2).

The unusual chemical shift values of H-6b in **1** (4.54 p.p.m.) and **2** (4.03 p.p.m.) were observed. Although it remains unclear, it was suggested that the observed chemical shift values might be due to the magnetic anisotropy effects of a 5,6-dihydro-4-hydroxy-2-pyrone moiety and a carbonyl group at C-7.

To our knowledge, mangromicins A (**1**) and B (**2**) are first natural products, which is an unprecedented structural skeleton of a cyclopentadecane with a tetrahydrofuran unit and a 5,6-dihydro-4-hydroxy-2-pyrone moiety.

Biological activities of mangromicins A (1) and B (2)

Mangromicins A and B were evaluated in a panel of assays, such as antimicrobial activities for pathogenic bacteria and fungi, antiviral activity, cancer cell cytotoxicity and antiparasitic activity for parasitic protozoan. In consequence, mangromicins A and B exhibited antitrypanosomal activities. As shown in Table 4, mangromicin A (**1**) showed potent activity against *Trypanosoma brucei brucei* GUTat 3.1 strain (*IC*₅₀ = 2.4 μg ml⁻¹), similar to that of the clinically used antitrypanosomal drugs, suramin and eflornithine. However, **1** exhibited more potent cytotoxicity against MRC-5 cells than both suramin and eflornithine. Mangromicin B (**2**) showed less potent antitrypanosomal and cytotoxic properties compared with **1** (*IC*₅₀ = 43.4 μg ml⁻¹). Therefore, the hydroxy group at C-9 position may have an important role to exert the antitrypanosomal and cytotoxic activities of the mangromicins.

METHODS

General experimental procedures

NMR spectra were measured using a Varian XL-400 and INOVA 600 (Varian, Palo Alto, CA, USA) or JEOL JNM-ECA 500 spectrometer (JEOL, Tokyo, Japan), with ¹H-NMR at 400, 500 or 600 MHz and ¹³C-NMR at 100, 125 or 150 MHz in CD₃OD or DMSO-*d*₆. The chemical shifts are expressed in p.p.m. and are referenced to residual CD₃OD (3.31 p.p.m.) or DMSO-*d*₆ (2.48 p.p.m.) in the ¹H-NMR spectra and CD₃OD (49 p.p.m.) or DMSO-*d*₆ (39.5 p.p.m.) in the ¹³C-NMR spectra. In the H/D exchange experiment, ¹³C NMR spectra were measured in CD₃OH.

LC-ESI-MS spectra were measured using an AB Sciex QSTAR Hybrid LC/MS/MS Systems (AB Sciex, Framingham, MA, USA). IR spectra (KBr) were taken on a Horiba FT-710 Fourier transform IR spectrometer (Horiba Ltd, Kyoto, Japan). UV spectra were measured with a Hitachi U-2810 spectrophotometer (Hitachi, Tokyo, Japan). Optical rotation was measured on a JASCO model DIP-1000 polarimeter (Jasco, Tokyo, Japan).

Taxonomic studies of strain K10-0216

The International *Streptomyces* Project media recommended by Shiring and Gottlieb²⁶ and by Waksman²⁷ were used to investigate cultural characteristics. Cultures were observed after incubation for 2 weeks at 27 °C. The morphological characteristics were observed by scanning electron microscope (JSM-5600; JEOL) after incubation on inorganic salts–starch agar for 4 weeks at 27 °C and fixation with 4% osmium tetroxide vapor. Isomers of diamino-pimelic acid in whole-cell hydrolysates were determined by TLC, following the standard methods of Becker *et al.*²⁸ and Hasegawa *et al.*²⁹ Menaquinones were extracted and purified by the method of Collins *et al.*³⁰ and then analyzed by LC/MS (JSM-T 100LP; JEOL) with a CAPCELL PAK C18 column (Shiseido, Tokyo, Japan) eluted with methanol/2-propanol (7:3). 16S rRNA gene sequence was amplified by PCR and sequenced on a 3130 Genetic Analyzer (Applied Biosystems, Carlsbad, CA, USA) using a BigDye Terminator v.3.1 cycle sequencing kit (Applied Biosystems) according to the manufacturer's instructions.

Fermentation

The strain K10-0216 was grown and maintained on agar slants, consisting of 1.0% starch, 0.3% NZ amine, 0.1% yeast extract, 0.1% meat extract, 1.2% agar and 0.3% CaCO₃. A loop of spores of strain K10-0216 was inoculated into 100 ml of the seed medium, consisting of 2.4% starch, 0.1% glucose, 0.3% peptone, 0.3% meat extract, 0.5% yeast extract and 0.4% CaCO₃ (adjusted to pH 7.0 before sterilization) in a 500-ml Erlenmeyer flask. The flask was incubated on a rotary shaker (210 r.p.m.) at 27 °C for 3 days. A 1-ml portion of the seed culture was transferred to 500-ml Erlenmeyer flasks (total 150) containing 100 ml of starch medium, consisting of 2% soluble starch, 0.5% glycerol, 1.0% defatted wheat germ, 0.3% meat extract, 0.3% dry yeast and 0.3% CaCO₃ (adjusted to pH 7.0 before sterilization) and fermentation was carried out on a rotary shaker (210 r.p.m.) at 27 °C for 7 days.

Esterification of mangromycin B (2) with MTPA chloride

To 1.0 mg of **2** was added 200 µl of anhydrous dichloromethane and 200 µl of anhydrous pyridine, followed by 50 µl of (R)- or (S)-MTPA chloride. The mixture was stirred for 16 h at room temperature. MeOH was added to the mixture for quenching. The organic solvents were removed *in vacuo* and 400 µl of H₂O and 1.2 ml of AcOEt were then added. The AcOEt layer was concentrated *in vacuo* and the respective (R)- or (S)-MTPA esters of **2** were independently purified by HPLC, using a semiprep column (C₁₈ (5 µm: 10 × 250 mm)) with isocratic (75% CH₃CN in H₂O) conditions for 40 min.

Crystallization method

Approximately 5.0 mg of **1** or **2** was placed in a polyspring glass insert with 10 µl of MeOH and 30 µl of H₂O and sealed inside an amber vial. The septum of the vial was pierced with a needle and the solution was evaporated for 16 h at 25 °C. Although a crystal of **1** was able to be evaluated with X-ray analysis, the crystal of **2** was of insufficient quality to allow examination using X-ray analysis.

X-ray crystallographic analysis of mangromycin A (1)

A colorless needle crystal of **1** was obtained from MeOH and H₂O. All measurements were made on a Rigaku-AXIS-Rapid II diffractometer (Rigaku, Tokyo, Japan) using graphite monochromated Cu–Kα radiation (λ = 1.54184 Å). The data were collected at 23 °C. The structure was solved by direct methods (SHELXS-97) and refined by full-matrix least-squares on F². All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were placed in ideal positions and refined using the riding model. Crystallographic data have been deposited in the Cambridge Crystallographic Data Center (Cambridge, UK) with the deposition number CCDC 947034. Copies of the data can be

obtained, free of charge, on application to the Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (e-mail: deposit@ccdc.cam.ac.uk). Detailed crystallographic information for mangromycin A is provided in the Supporting Information (CIF). The crystal data were monoclinic, space group P2₁, *a* = 12.8526(6) Å, *b* = 13.1817(5) Å, *c* = 13.4389(5) Å, *b* = 93.159(2)°, *V* = 2273.3(2) Å³ and *Z* = 4.

Antitrypanosomal activity in vitro

In vitro antitrypanosomal activities against *T. brucei brucei* strain GUTat 3.1 were measured, using the method described previously.³¹ In brief, the strain GUTat 3.1 was cultured in Iscove's modified Dulbecco's media with various supplements and 10% heat-inactivated fetal bovine serum at 37 °C, under 5.0% CO₂–95% air. Subsequently, 95 µl of the trypanosome suspension (2.0–2.5 × 10⁴ trypanosomes per ml) was transferred into a 96-well microtiter plate and 5.0 µl of a test compound solution (dissolved in 5.0% DMSO) was added and the plate incubated for 72 h at 37 °C (long incubation–low inoculation test). Subsequently, 10 µl of the fluorescent dye Alamar Blue was added to each well. After incubation for 3–6 h, the resulting solution was read at 528/20 nm excitation wavelengths and 590/30 nm emission wavelengths using an FLx800 fluorescence microplate reader (BioTek Instruments, Winooski, VT, USA). The IC₅₀ values were determined using the fluorescent plate reader software (KC-4; BioTek Instruments). Successive subcultures were carried out in 24-well tissue culture plates under the same conditions.

Cytotoxic activity in vitro

Measurement of cytotoxic activity against human fetal lung fibroblast MRC-5 cells was carried out as described previously.³²

ACKNOWLEDGEMENTS

This study was supported, in part, by funds from Quality Assurance Framework of Higher Education from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan and the institute for Fermentation (IFO), Osaka, Japan. We are grateful to Ms Noriko Sato, School of Pharmacy, Kitasato University, for measurements of NMR spectra, Ms Miyuki Namatame and Dr Tomoyasu Hirose, Kitasato Institute for Life Sciences, Kitasato University, for antitrypanosomal and cytotoxic assay and advice on the structure, respectively.

- 1 Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. *J. Nat. Prod.* **75**, 311–335 (2012).
- 2 Bérty, J. Bioactive microbial metabolites. *J. Antibiot.* **58**, 1–26 (2005).
- 3 Chin, Y. W., Balunas, M. J., Chai, H. B. & Kinghorn, A. D. Drug discovery from natural sources. *AAPS J.* **8**, E239–E253 (2006).
- 4 Peano, C. *et al.* Comparative genomics and transcriptional profiles of *Saccharopolyspora erythraea* NRRL 2338 and a classically improved erythromycin over-producing strain. *Microb. Cell Fact.* **11**, 32 (2012).
- 5 Bentley, S. D. *et al.* Complete genome sequence of the model actinomycete *Streptomyces coelicolor* A3(2). *Nature* **417**, 141–147 (2002).
- 6 Ōmura, S. *et al.* Genome sequence of an industrial microorganism *Streptomyces avermitilis*: deducing the ability of producing secondary metabolites. *Proc. Natl Acad. Sci. USA* **98**, 12215–12220 (2001).
- 7 Ohnishi, Y. *et al.* Genome sequence of the streptomycin-producing microorganism *Streptomyces griseus* IFO 13350. *J. Bacteriol.* **190**, 4050–4060 (2008).
- 8 Flårdh, K. & Buttner, M. J. *Streptomyces morphogenetics*: dissecting differentiation in a filamentous bacterium. *Nat. Rev. Microbiol.* **7**, 36–49 (2009).
- 9 Scherlach, K. & Hertweck, C. Triggering cryptic natural product biosynthesis in microorganisms. *Org. Biomol. Chem.* **7**, 1753–1760 (2009).
- 10 Li, J. W. & Vederas, J. C. Drug discovery and natural products: end of an era or an endless frontier? *Science* **325**, 161–165 (2009).
- 11 Ōmura, S. *et al.* A new alkaloid AM-2282 of *Streptomyces* origin. Taxonomy, fermentation, isolation and preliminary characterization. *J. Antibiot.* **30**, 275–282 (1977).
- 12 Xie, Q. *et al.* Description of *Lentzea flaviverrucosa* sp. nov. and transfer of the type strain of *Saccharothrix aerocolonigenes* subsp. *staurosporea* to *Lentzea albida*. *Int. J. Syst. Evol. Microbiol.* **52**, 1815–1820 (2002).
- 13 Takahashi, Y., Shinose, M., Seino, A., Iwai, Y. & Ōmura, S. Transfer of staurosporine-producing strain *Streptomyces staurosporeus* AM-2282 to the genus *Saccharothrix* as *Saccharothrix aerocolonigenes* (Labeda 1986) subsp. *Actinomycetologica* **9**, 19–26 (1995).
- 14 Tamaoki, T. *et al.* Staurosporine, a potent inhibitor of phospholipid/Ca⁺⁺ dependent protein kinase. *Biochem. Biophys. Res. Commun.* **135**, 397–402 (1986).
- 15 Ōmura, S., Sasaki, Y., Iwai, Y. & Takeshima, H. Staurosporine, a potentially important gift from a microorganism. *J. Antibiot.* **48**, 535–548 (1995).

- 16 Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. *Nat. Rev. Drug Discov.* **1**, 493–502 (2002).
- 17 Nakano, H. & Ōmura, S. Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine. *J. Antibiot.* **62**, 17–26 (2009).
- 18 Kamiya, Y. *et al.* in *Abstract of the 2013 Annual Meeting of the Society for Actinomycetes Japan*. The Society for Actinomycetes Japan, Hiroshima, Japan, pp 75 (2013).
- 19 Ōmura, S. *et al.* (The Kitasato Institute). *Novel Mangromicin Compound and Production Method Therefore*. WO 2013031239 (7 March 2013).
- 20 Labeda, D. P. *et al.* Revival of the genus *Lentzea* and proposal for *Lechevalieria* gen. nov. *Int. J. Syst. Evol. Microbiol.* **51**, 1045–1050 (2001).
- 21 Smirnov, S. N. *et al.* Hydrogen/deuterium isotope effects on the NMR chemical shifts and geometries of intermolecular low-barrier hydrogen-bonded complexes. *J. Am. Chem. Soc.* **118**, 4094–4101 (1996).
- 22 Dale, J. A., Dull, D. L. & Mosher, H. S. α -Methoxy- α -trifluoromethylphenylacetic acid, a versatile reagent for the determination of enantiomeric composition of alcohols and amines. *J. Org. Chem.* **34**, 2543–2549 (1969).
- 23 Dale, J. A. & Mosher, H. S. Nuclear magnetic resonance enantiomer reagents. Configurational correlations via nuclear magnetic resonance chemical shifts of diastereomeric mandelate, *O*-methylmandelate, and α -methoxy- α -trifluoromethylphenylacetate (MTPA) esters. *J. Am. Chem. Soc.* **95**, 512–519 (1973).
- 24 Sullivan, G. R., Dale, J. A. & Mosher, H. S. Correlation of configuration and fluorine-19 chemical shifts of α -methoxy- α -trifluoromethylphenyl acetate derivatives. *J. Org. Chem.* **38**, 2143–2147 (1973).
- 25 Seco, J., Martino, M., Quinoa, E. & Riguera, R. Absolute configuration of 1,*n*-diols by NMR: the importance of the combined anisotropic effects in bis-aryl methoxyacetates. *Org. Lett.* **2**, 3261–3264 (2000).
- 26 Shirling, E. B. & Gottlieb, D. Methods for characterization of *Streptomyces* species. *Int. J. Syst. Bacteriol.* **16**, 313–340 (1966).
- 27 Waksman, S. A. (ed.) *The Actinomycetes* Vol. 2. Williams and Wilkins, Baltimore, MD (1961).
- 28 Becker, B., Lechevalier, M. P. & Lechevalier, H. A. Chemical composition of cell-wall preparation from strains of various form-genera of aerobic actinomycetes. *Appl. Microbiol.* **13**, 236–243 (1965).
- 29 Hasegawa, T., Takizawa, M. & Tanida, S. A rapid analysis for chemical grouping of aerobic actinomycetes. *J. Gen. Appl. Microbiol.* **29**, 319–322 (1983).
- 30 Collins, M. D., Goodfellow, M. & Minnikin, D. E. Distribution of menaquinones in actinomycetes and corynebacteria. *J. Gen. Microbiol.* **100**, 221–230 (1977).
- 31 Otoguro, K. *et al.* Selective and potent *in vitro* antitrypanosomal activities of ten microbial metabolites. *J. Antibiot.* **61**, 372–378 (2008).
- 32 Otoguro, K. *et al.* Potent antimalarial activities of polyether antibiotic, X-206. *J. Antibiot.* **54**, 658–663 (2001).

Supplementary Information accompanies the paper on The Journal of Antibiotics website (<http://www.nature.com/ja>)